Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

Residual symptoms and cognitive impairment are among important sources of disability in patients with bipolar disorder.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Thirty-seven participants were enrolled in a 6-month trial (trial registration: NCT00214877).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Methylene blue (non-peptide stack partner), giving a reference point.

Each person switched between Methylene blue (non-peptide stack partner) and the comparison at some point, usually with a gap in between.

The outcome measures included severity of depression, mania and anxiety, and cognitive functioning.

What Was Measured

PubMed files the paper under topics including Anxiety, Bipolar Disorder, Cognitive Dysfunction, Depression, Enzyme Inhibitors, Excitatory Amino Acid Antagonists and Lamotrigine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (The British journal of psychiatry : the journal of mental science), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.